Logo
x

Search

Subscribe Now

Tecentriq

Roche Reports Updated OS Data of Tecentriq + Avastin in P-III IMbrave150 Study for Unresectable HCC

Roche Reports Updated OS Data of Tecentriq + Avastin in P-III IMbrave150 Study for Unresectable HCC

  • January 12, 2021
Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma

Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma

  • November 3, 2020
Chugai's Tecentriq (atezolizumab) and Avastin (bevacizumab) Receive MHLW's Approval as 1L Treatment for Unresectable Hepatocellular Carcinoma

Chugai's Tecentriq (atezolizumab) and Avastin (bevacizumab) Receive MHLW's Approval as 1L Treatment for Unresectable Hepatocellula...

  • September 28, 2020
Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

  • September 21, 2020
Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020

Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020

  • September 17, 2020
Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Car...

  • August 19, 2020
Top 20 Monoclonal Antibodies Based on 2022 Total Revenue 

    Top 20 Monoclonal Antibodies Based on 2022 Total Revenue 

    • September 26, 2023
    Genentech Reports Second Interim Analysis Results from the P-III Study (SKYSCRAPER-01) of Tiragolumab + Tecentriq for PD-L1-High Metastatic Non-Small Cell Lung Cancer

      Genentech Reports Second Interim Analysis Results from the P-III Study (SKYSCRAPER-01) of Tiragolumab + Tecentriq for PD-L1-High M...

      • August 23, 2023
      Nykode Therapeutics Reports Final P-II Trial (VB-C-02) Results of VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer

        Nykode Therapeutics Reports Final P-II Trial (VB-C-02) Results of VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer

        • April 19, 2023
        Genentech Reports P-III Study (IMbrave050) Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) for Early-Stage Liver Cancer

          Genentech Reports P-III Study (IMbrave050) Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) for Early-Stage Liver Cance...

          • January 19, 2023
          Roche Reports P-III (IMscin001) Study Results of Subcutaneous Formulation of Tecentriq for the Treatment of Non-Small Cell Lung Cancer

            Roche Reports P-III (IMscin001) Study Results of Subcutaneous Formulation of Tecentriq for the Treatment of Non-Small Cell Lung Ca...

            • August 2, 2022
            Roche Reports Interim Results of Tiragolumab + Tecentriq (atezolizumab) in P-III (SKYSCRAPER-01) Study for PD-L1-High Metastatic Non-Small Cell Lung Cancer

              Roche Reports Interim Results of Tiragolumab + Tecentriq (atezolizumab) in P-III (SKYSCRAPER-01) Study for PD-L1-High Metastatic N...

              • May 12, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.